Finasteride Management During Post‑Cycle Therapy for Fertility Restoration

Mechanistic Basis of Post‑Cycle Therapy

Human chorionic gonadotropin (HCG) directly stimulates Leydig cells in the testes to produce testosterone, mimicking luteinizing hormone (LH). This action is central to restoring endogenous testosterone during PCT. 1
Clomiphene antagonizes estrogen receptors in the hypothalamus, leading to increased GnRH secretion and subsequent release of FSH and LH, which together promote testosterone synthesis and spermatogenesis. This dual effect supports both hormonal recovery and sperm production. 1

Finasteride should be stopped for the entire duration of the PCT protocol because the regimen is specifically designed to restore fertility and endogenous testosterone production. Continuing a drug that impairs semen volume and motility directly opposes the therapeutic goal of PCT. 1

During the limited window of PCT, recovery of fertility and hormonal balance should take precedence over the benefits of finasteride for androgenic alopecia or prostate size reduction. Resuming finasteride can be considered only after confirming successful fertility restoration. 1

Finasteride’s modest increase in serum testosterone does not aid PCT because it works by inhibiting conversion of testosterone to dihydrotestosterone (DHT), whereas PCT aims to reactivate the entire hypothalamic‑pituitary‑gonadal axis suppressed by exogenous testosterone. Therefore, finasteride does not support the hormonal recovery targeted by PCT. 1

The American Urological Association/American Society for Reproductive Medicine 2024 guidelines state that finasteride 1mg/day has inconclusive evidence regarding its impact on fertility, while the 5mg dose is associated with reduced semen volume 2
Finasteride inhibits the 5-alpha-reductase enzyme, which converts testosterone to dihydrotestosterone (DHT), potentially affecting sexual function 3

Sexual side effects of finasteride, such as erectile dysfunction and decreased libido, may indirectly affect fertility by impacting sexual function, occurring in approximately 2-4% more patients taking finasteride compared to placebo 4, 3
The magnitude of sexual dysfunction effect is relatively small compared to natural aging, with finasteride's effect being a mean difference of 3.21 points on sexual function scales, compared to 1.26 points for each year of aging 4

Discontinuation rates due to adverse events are approximately 6-7% in both finasteride and placebo groups in clinical trials 3